Literature DB >> 18667411

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Virginia Espina1, Kirsten H Edmiston, Michael Heiby, Mariaelena Pierobon, Manuela Sciro, Barbara Merritt, Stacey Banks, Jianghong Deng, Amy J VanMeter, David H Geho, Lucia Pastore, Joel Sennesh, Emanuel F Petricoin, Lance A Liotta.   

Abstract

Little is known about the preanalytical fluctuations of phosphoproteins during tissue procurement for molecular profiling. This information is crucial to establish guidelines for the reliable measurement of these analytes. To develop phosphoprotein profiles of tissue subjected to the trauma of excision, we measured the fidelity of 53 signal pathway phosphoproteins over time in tissue specimens procured in a community clinical practice. This information provides strategies for potential surrogate markers of stability and the design of phosphoprotein preservative/fixation solutions. Eleven different specimen collection time course experiments revealed augmentation (+/-20% from the time 0 sample) of signal pathway phosphoprotein levels as well as decreases over time independent of tissue type, post-translational modification, and protein subcellular location (tissues included breast, colon, lung, ovary, and uterus (endometrium/myometrium) and metastatic melanoma). Comparison across tissue specimens showed an >20% decrease of protein kinase B (AKT) Ser-473 (p < 0.002) and myristoylated alanine-rich C-kinase substrate protein Ser-152/156 (p < 0.0001) within the first 90-min postexcision. Proteins in apoptotic (cleaved caspase-3 Asp-175 (p < 0.001)), proliferation/survival/hypoxia (IRS-1 Ser-612 (p < 0.0003), AMP-activated protein kinase beta Ser-108 (p < 0.005), ERK Thr-202/Tyr-204 (p < 0.003), and GSK3alphabeta Ser-21/9 (p < 0.01)), and transcription factor pathways (STAT1 Tyr-701 (p < 0.005) and cAMP response element-binding protein Ser-133 (p < 0.01)) showed >20% increases within 90-min postprocurement. Endothelial nitric-oxide synthase Ser-1177 did not change over the time period evaluated with breast or leiomyoma tissue. Treatment with phosphatase or kinase inhibitors alone revealed that tissue kinase pathways are active ex vivo. Combinations of kinase and phosphatase inhibitors appeared to stabilize proteins that exhibited increases in the presence of phosphatase inhibitors alone (ATF-2 Thr-71, SAPK/JNK Thr-183/Tyr-185, STAT1 Tyr-701, JAK1 Tyr-1022/1023, and PAK1/PAK2 Ser-199/204/192/197). This time course study 1) establishes the dynamic nature of specific phosphoproteins in excised tissue, 2) demonstrates augmented phosphorylation in the presence of phosphatase inhibitors, 3) shows that kinase inhibitors block the upsurge in phosphorylation of phosphoproteins, 4) provides a rational strategy for room temperature preservation of proteins, and 5) constitutes a foundation for developing evidence-based tissue procurement guidelines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667411      PMCID: PMC2559936          DOI: 10.1074/mcp.M700596-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  27 in total

1.  Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma.

Authors:  Christian Gulmann; Virginia Espina; Emanuel Petricoin; Dan L Longo; Mariarita Santi; Turid Knutsen; Mark Raffeld; Elaine S Jaffe; Lance A Liotta; Andrew L Feldman
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays.

Authors:  Imran H Khan; Sara Mendoza; Paul Rhyne; Melanie Ziman; Joseph Tuscano; Dominic Eisinger; Hsing-Jien Kung; Paul A Luciw
Journal:  Mol Cell Proteomics       Date:  2005-12-20       Impact factor: 5.911

Review 3.  Phosphoproteomic approaches to elucidate cellular signaling networks.

Authors:  Katrin Schmelzle; Forest M White
Journal:  Curr Opin Biotechnol       Date:  2006-06-27       Impact factor: 9.740

4.  Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis.

Authors:  K-F Becker; C Schott; S Hipp; V Metzger; P Porschewski; R Beck; J Nährig; I Becker; H Höfler
Journal:  J Pathol       Date:  2007-02       Impact factor: 7.996

Review 5.  DAMPs, PAMPs and alarmins: all we need to know about danger.

Authors:  Marco E Bianchi
Journal:  J Leukoc Biol       Date:  2006-10-10       Impact factor: 4.962

Review 6.  Proteins, drug targets and the mechanisms they control: the simple truth about complex networks.

Authors:  Robyn P Araujo; Lance A Liotta; Emanuel F Petricoin
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

7.  The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.

Authors:  Sze Chuen Cesar Wong; John K C Chan; Elena S F Lo; Amanda K C Chan; Manson C K Wong; Charles M L Chan; Money Y Y Lam; Anthony T C Chan
Journal:  Arch Pathol Lab Med       Date:  2007-07       Impact factor: 5.534

8.  The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

Authors:  Amy Rapkiewicz; Virginia Espina; Jo Anne Zujewski; Peter F Lebowitz; Armando Filie; Julia Wulfkuhle; Kevin Camphausen; Emanuel F Petricoin; Lance A Liotta; Andrea Abati
Journal:  Cancer       Date:  2007-06-25       Impact factor: 6.860

Review 9.  Analysis of protein phosphorylation on a proteome-scale.

Authors:  Mark O Collins; Lu Yu; Jyoti S Choudhary
Journal:  Proteomics       Date:  2007-08       Impact factor: 3.984

10.  AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies.

Authors:  Sylvia M Major; Satoshi Nishizuka; Daisaku Morita; Rick Rowland; Margot Sunshine; Uma Shankavaram; Frank Washburn; Daniel Asin; Hosein Kouros-Mehr; David Kane; John N Weinstein
Journal:  BMC Bioinformatics       Date:  2006-04-06       Impact factor: 3.169

View more
  82 in total

1.  [Update on protein analysis of fixed tissues].

Authors:  K-F Becker; D Berg; K Malinowsky; C Wolff; B Ergin; S Meding; A Walch; H Höfler
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease.

Authors:  Temple A Douglas; Davide Tamburro; Claudia Fredolini; Benjamin H Espina; Benjamin S Lepene; Leopold Ilag; Virginia Espina; Emanuel F Petricoin; Lance A Liotta; Alessandra Luchini
Journal:  Biomaterials       Date:  2010-10-28       Impact factor: 12.479

3.  Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability.

Authors:  Virginia Espina; Claudius Mueller; Kirsten Edmiston; Manuela Sciro; Emanuel F Petricoin; Lance A Liotta
Journal:  Proteomics Clin Appl       Date:  2009-08-01       Impact factor: 3.494

Review 4.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

5.  Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology.

Authors:  Juraj Bodo; Lisa Durkin; Eric D Hsi
Journal:  J Histochem Cytochem       Date:  2009-03-30       Impact factor: 2.479

6.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 7.  The impact of biosampling procedures on molecular data interpretation.

Authors:  Karl Sköld; Henrik Alm; Birger Scholz
Journal:  Mol Cell Proteomics       Date:  2013-02-04       Impact factor: 5.911

8.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

9.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Authors:  Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2012-10-22       Impact factor: 13.506

10.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.